07 Jul Value of H-FABP as Potential Biomarker of Pulmonary Embolism
MedicalResearch.com Interview with:
Dr. Liang He
Department of Anesthesiology
Yan’an Hospital of Kunming City, kunming, 650051, China
MedicalResearch: What are the main findings of this study?
Dr. He: We evaluated the prognostic value of plasma heart-type fatty acid binding protein (H-FABP) in patients with acute pulmonary embolism (PE) with the guidelines of acute PE of European Society Cardiology (ESC).
We found that higher H-FABP level (above 6 or 7 ng/ml) was associated with an increased of 30-d mortality and complicated clinical events, from six studies of 85 articles included. H-FABP has the potential to be a novel prognostic marker that can help optimize patient management strategies and risk-stratification algorithms in the population of patients with acute pulmonary embolism. However, few studies had been specifically designed to answer our research questions.
Our pooled estimates of prognostic performance are not adjusted for confounding factors such as age, sex, hemodynamic, methodologies, or history of heart function. Therefore, sound prospective cohort, multi-center and large sample studies with definitions of acute PE under international guidelines are required to further increase confidence in the value of H-FABP.
Published online July 03, 2014. doi:10.1378/chest.13-1008